Single-Cell Multi-Omics and Cell-Type-Specific Molecular Mechanisms in Parkinson's Disease: From Human Substantia Nigra Atlas to Precision Therapeutics

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease and represents a growing public health concern worldwide. It is characterized by the progressive degeneration of dopaminergic neurons within the substantia nigra pars compacta, resulting in dopamine deficiency and impairment of motor function. Although the hallmark symptoms include resting tremor, bradykinesia, rigidity, and postural instability, PD also presents with a wide range of non-motor manifestations such as cognitive impairment, depression, autonomic dysfunction, sleep disturbances, and olfactory deficits, which significantly affect patients' quality of life. Despite decades of research, the precise molecular mechanisms underlying PD remain incompletely understood due to the complex interactions among genetic susceptibility, environmental exposures, aging, mitochondrial dysfunction, protein aggregation, neuroinflammation, and oxidative stress (Bloem et al., 2021; Poewe et al., 2017).

Recent advances in high-throughput sequencing technologies have transformed our understanding of PD pathogenesis. Conventional bulk transcriptomic and proteomic analyses have provided valuable insights into disease-associated molecular pathways; however, these approaches average gene expression across heterogeneous cell populations and fail to capture cell-type-specific alterations. The emergence of single-cell and single-nucleus sequencing technologies has overcome these limitations by enabling comprehensive profiling of individual cells within the human brain. These technologies have uncovered previously unrecognized cellular heterogeneity within the substantia nigra and identified distinct molecular signatures associated with dopaminergic neurons, astrocytes, microglia, oligodendrocytes, endothelial cells, and oligodendrocyte precursor cells. Such discoveries have opened new opportunities for biomarker identification, precision therapeutics, and personalized medicine in PD (Agarwal et al., 2020; Smajić et al., 2022).

This review summarizes current advances in single-cell multi-omics approaches and highlights how cell-type-specific molecular mechanisms contribute to Parkinson's disease. It further discusses emerging biomarkers, therapeutic targets, artificial intelligence-assisted analyses, and future perspectives for translating single-cell discoveries into precision medicine.

1.1 Parkinson's Disease: Global Burden

Epidemiology

Parkinson's disease affects more than 10 million people worldwide, and its prevalence continues to increase because of population aging and improved life expectancy. The incidence rises sharply after the age of 60 years, although approximately 5–10% of patients develop early-onset PD before the age of 50. Men are affected slightly more frequently than women. According to recent estimates from the Global Burden of Disease Study, the number of individuals living with PD has more than doubled over the past three decades, making it one of the fastest-growing neurological disorders globally (GBD 2021 Parkinson's Disease Collaborators, 2024; Bloem et al., 2021).

Economic Burden

Parkinson's disease imposes a substantial economic burden on patients, caregivers, and healthcare systems. Direct medical costs include hospitalization, medications, rehabilitation, surgical interventions, and long-term care, while indirect costs arise from loss of productivity, disability, and caregiver support. As disease severity progresses, healthcare expenditures increase considerably due to complications and the need for continuous multidisciplinary management (Yang et al., 2020; Bloem et al., 2021).

Clinical Manifestations

The clinical presentation of PD extends beyond classical motor symptoms. Motor manifestations include resting tremor, bradykinesia, muscular rigidity, gait impairment, and postural instability. Non-motor symptoms such as depression, anxiety, cognitive decline, constipation, sleep disorders, anosmia, and autonomic dysfunction often precede motor signs by several years, indicating that neurodegeneration begins long before clinical diagnosis (Poewe et al., 2017).

Disease Progression

Parkinson's disease is a chronic progressive disorder characterized by gradual neuronal loss and increasing neurological disability. Disease progression varies considerably among individuals and is influenced by age, genetic background, environmental factors, and comorbidities. With advancing disease, patients often develop motor fluctuations, dyskinesias, cognitive impairment, and dementia, highlighting the urgent need for disease-modifying therapies (Bloem et al., 2021).

1.2 Neuropathology of Parkinson's Disease

Loss of Dopaminergic Neurons

The defining pathological feature of PD is the selective degeneration of dopaminergic neurons located in the substantia nigra pars compacta. The depletion of these neurons reduces dopamine availability within the nigrostriatal pathway, leading to impaired motor control and the characteristic movement abnormalities observed in PD. Single-cell transcriptomic studies have revealed that vulnerable dopaminergic neuron subpopulations exhibit distinct molecular signatures associated with mitochondrial dysfunction, impaired protein degradation, and metabolic stress (Agarwal et al., 2020).

α-Synuclein Aggregation

Misfolding and aggregation of α-synuclein represent central events in PD pathogenesis. Abnormal α-synuclein undergoes conformational changes, forms toxic oligomers and fibrils, and spreads between neurons in a prion-like manner. These aggregates interfere with synaptic transmission, mitochondrial function, vesicle trafficking, and intracellular protein homeostasis, ultimately promoting neuronal death (Poewe et al., 2017).

Lewy Body Formation

Lewy bodies are intracellular protein inclusions primarily composed of aggregated α-synuclein along with ubiquitin and other cellular proteins. They are considered one of the neuropathological hallmarks of PD and are widely distributed throughout the central and peripheral nervous systems. Their progressive accumulation correlates with disease severity and the emergence of cognitive dysfunction (Braak et al., 2003).

Neuroinflammation

Persistent activation of microglia and astrocytes contributes significantly to PD progression. Activated glial cells release pro-inflammatory cytokines, chemokines, reactive oxygen species, and nitric oxide, creating a neurotoxic environment that accelerates dopaminergic neuron degeneration. Single-cell analyses have demonstrated substantial heterogeneity among glial populations, suggesting that distinct inflammatory states influence disease progression differently (Agarwal et al., 2020; Smajić et al., 2022).

Oxidative Stress

Oxidative stress plays a major role in neuronal degeneration by disrupting mitochondrial respiration and increasing reactive oxygen species production. Dopaminergic neurons are particularly susceptible because dopamine metabolism itself generates reactive intermediates. Excessive oxidative damage affects proteins, lipids, and DNA, leading to impaired cellular function and apoptosis (Dexter & Jenner, 2013).

1.3 Limitations of Conventional Molecular Studies

Traditional molecular approaches, including bulk RNA sequencing, microarray analysis, and proteomics, have substantially improved our understanding of PD biology. However, these techniques measure averaged molecular signals across mixed cell populations, masking important differences between individual cell types. Consequently, rare neuronal populations and disease-specific cellular responses often remain undetected. This limitation has hindered the identification of precise therapeutic targets and early biomarkers, particularly within the highly heterogeneous cellular environment of the substantia nigra (Agarwal et al., 2020).

1.4 Emergence of Single-Cell Technologies

The introduction of single-cell and single-nucleus sequencing technologies has revolutionized neuroscience research by enabling high-resolution analysis of individual cells. Modern platforms, including single-cell RNA sequencing (scRNA-seq), single-nucleus RNA sequencing (snRNA-seq), single-cell ATAC-seq, spatial transcriptomics, and integrated multi-omics approaches, allow researchers to characterize cellular diversity, gene regulatory networks, and intercellular communication with unprecedented precision. These technologies have identified previously unrecognized neuronal and glial subpopulations, revealed disease-associated molecular pathways, and accelerated biomarker discovery and precision therapeutic development for Parkinson's disease (Agarwal et al., 2020; Smajić et al., 2022).

1.5 Scope and Objectives of the Review

This review aims to provide a concise overview of recent advances in single-cell multi-omics technologies and their applications in Parkinson's disease research. It focuses on the cellular architecture of the human substantia nigra, cell-type-specific molecular mechanisms underlying neurodegeneration, and the integration of transcriptomic, epigenomic, proteomic, and metabolomic data. In addition, the review highlights emerging biomarkers, novel therapeutic targets, artificial intelligence-assisted analytical approaches, and future directions for translating single-cell discoveries into precision medicine.

2. HUMAN SUBSTANTIA NIGRA: CELLULAR ARCHITECTURE AND FUNCTIONAL ORGANIZATION

The substantia nigra (SN) is a highly specialized structure located in the ventral midbrain and is a central component of the basal ganglia circuitry responsible for regulating voluntary movement, motor learning, reward processing, and cognitive functions. It is anatomically divided into two major regions: the substantia nigra pars compacta (SNpc) and the substantia nigra pars reticulata (SNpr). The SNpc contains densely packed dopaminergic neurons that project to the dorsal striatum through the nigrostriatal pathway, whereas the SNpr is primarily composed of GABAergic neurons that serve as one of the principal output nuclei of the basal ganglia. Progressive degeneration of dopaminergic neurons within the SNpc is the pathological hallmark of Parkinson's disease (PD), leading to dopamine depletion and subsequent impairment of motor function (Poewe et al., 2017; Bloem et al., 2021).

Recent advances in single-cell RNA sequencing (scRNA-seq) and single-nucleus RNA sequencing (snRNA-seq) have transformed our understanding of the human substantia nigra by revealing remarkable cellular diversity. Rather than consisting solely of dopaminergic neurons, the SN contains multiple neuronal and non-neuronal cell populations, including astrocytes, microglia, oligodendrocytes, oligodendrocyte precursor cells (OPCs), endothelial cells, and pericytes. Each cell type possesses unique transcriptional signatures and contributes differently to neuronal homeostasis, synaptic function, immune regulation, myelin maintenance, and neurovascular integrity. Single-cell transcriptomic atlases have demonstrated that these diverse cellular populations exhibit disease-specific molecular alterations in Parkinson's disease, highlighting their collective role in disease initiation and progression (Agarwal et al., 2020; Smajić et al., 2022).

2.1 Anatomy of the Substantia Nigra

The substantia nigra forms part of the extrapyramidal motor system and extends throughout the midbrain between the cerebral peduncles and the tegmentum. Anatomically, it consists of two functionally distinct subdivisions.

The substantia nigra pars compacta (SNpc) is characterized by pigmented dopaminergic neurons containing neuromelanin. These neurons synthesize dopamine and project extensively to the caudate nucleus and putamen, where dopamine modulates the balance between the direct and indirect motor pathways. Dopamine deficiency resulting from neuronal degeneration disrupts this balance, producing the characteristic motor symptoms of PD.

In contrast, the substantia nigra pars reticulata (SNpr) is composed predominantly of inhibitory GABAergic neurons. These neurons receive input from the striatum and subthalamic nucleus and transmit inhibitory signals to the thalamus and superior colliculus, thereby regulating movement initiation, eye movements, and postural control.

Besides neuronal populations, the SN contains abundant glial cells and vascular components that maintain metabolic support, immune surveillance, and blood–brain barrier integrity. Modern transcriptomic studies indicate that glial cells outnumber neurons in the adult substantia nigra, emphasizing their critical contribution to both physiological function and neurodegeneration (Agarwal et al., 2020).

 

 

Figure 1 Anatomy of Substantia Nigra

 

 

Figure 2: Cellular Architecture and Functional Organization of the Human Substantia Nigra

 

 

Figure 3: Pathogenesis of Parkinson’s Disease

 

 

Figure 4: Dopminergic Mechanisms in Parkinson's Disease

 

 

Figure 5: GABAergic Mechanisms in Parkinson's Disease

 

 

Figure 6: Astrocytic Mechanisms in Parkinson's Disease

 

 

Figure 7: Microglia Mechanisms in Parkinson's Disease

 

 

Figure 8: Oligodendrocyte Mechanisms in Parkinson's Disease

 

 

Figure 9: Oligodendrocyte Precursor Cells Mechanisms in Parkinson's Disease

 

 

Figure 10: Endothelial Cell Mechanisms in Parkinson's Disease

6. MULTI-OMICS INTEGRATION IN PARKINSON'S DISEASE

Single-omics approaches have significantly improved our understanding of Parkinson's disease (PD), but each technique captures only one aspect of the disease process. Since PD results from complex interactions among genetic, epigenetic, transcriptomic, proteomic, and metabolic alterations, integrating multiple omics datasets provides a more comprehensive understanding of disease mechanisms. Multi-omics approaches enable researchers to identify interconnected molecular pathways, discover robust biomarkers, and develop precision therapeutic strategies. Recent advances in computational biology and artificial intelligence (AI) have further enhanced the integration of diverse omics datasets, allowing high-resolution characterization of disease-associated cellular networks and individual patient variability (Hasin et al., 2017; Smajić et al., 2022).

By combining single-cell technologies with multi-omics analyses, researchers can simultaneously investigate gene expression, chromatin accessibility, protein abundance, metabolite profiles, and cellular interactions within the same tissue. This integrated strategy has revealed that Parkinson's disease is driven by coordinated dysfunction across multiple biological systems rather than alterations in a single molecular pathway. Consequently, multi-omics integration is becoming a cornerstone of precision medicine for early diagnosis, disease monitoring, and personalized treatment development (Agarwal et al., 2020).

6.1 Transcriptomics

Transcriptomics examines the complete set of RNA transcripts expressed within a cell or tissue. Single-cell RNA sequencing (scRNA-seq) and single-nucleus RNA sequencing (snRNA-seq) have identified disease-specific transcriptional changes in dopaminergic neurons, astrocytes, microglia, oligodendrocytes, and endothelial cells. These studies have highlighted dysregulated pathways involved in mitochondrial function, synaptic signaling, oxidative stress, protein degradation, and neuroinflammation, providing valuable insight into the molecular basis of PD (Agarwal et al., 2020; Smajić et al., 2022).

6.2 Epigenomics

Epigenomics investigates heritable changes in gene regulation that occur without altering the DNA sequence. DNA methylation, histone modifications, and chromatin remodeling influence neuronal survival and inflammatory responses in PD. Single-cell epigenomic studies have demonstrated cell-specific alterations in chromatin accessibility and transcription factor activity, suggesting that epigenetic dysregulation contributes to selective neuronal vulnerability and disease progression (Corces et al., 2020).

6.3 Proteomics

Proteomics provides direct information about protein expression, post-translational modifications, and signaling pathways. Since proteins perform most cellular functions, proteomic analyses complement transcriptomic data by identifying functional changes that cannot be predicted from RNA expression alone. In PD, proteomics has revealed abnormalities in α-synuclein processing, mitochondrial proteins, inflammatory mediators, and components of the ubiquitin–proteasome system, offering potential biomarkers and therapeutic targets (Kelly, 2020).

6.4 Metabolomics

Metabolomics measures small molecules produced during cellular metabolism, providing a direct indication of cellular function. Metabolic profiling in PD has identified disturbances in energy metabolism, lipid synthesis, amino acid metabolism, and oxidative stress pathways. These metabolic alterations reflect mitochondrial dysfunction and impaired neuronal bioenergetics, which are central features of Parkinson's disease (Johnson et al., 2021).

6.5 Lipidomics

Lipidomics focuses on the comprehensive analysis of cellular lipids involved in membrane integrity, signaling, and energy storage. Altered lipid metabolism has been associated with α-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation in PD. Changes in phospholipids, sphingolipids, and cholesterol metabolism may influence neuronal survival and disease progression, making lipidomic profiling a promising approach for biomarker discovery (Fanning et al., 2020).

6.6 Genomics

Genomic studies identify inherited and acquired genetic variations associated with Parkinson's disease. Mutations in genes such as SNCA, LRRK2, PARK2, PINK1, DJ-1, and GBA1 increase disease susceptibility by affecting mitochondrial quality control, lysosomal degradation, and protein homeostasis. Integrating genomic information with transcriptomic and proteomic data helps establish functional relationships between genetic variants and downstream cellular alterations (Blauwendraat et al., 2020).

6.7 Integrated Multi-Omics Networks

Integrated multi-omics combines genomic, transcriptomic, epigenomic, proteomic, metabolomic, and lipidomic datasets to construct comprehensive molecular networks. Machine learning and AI-based computational models identify interactions among genes, proteins, metabolites, and signaling pathways that are not apparent when each dataset is analyzed independently. These integrated networks improve biomarker identification, patient stratification, prediction of disease progression, and discovery of personalized therapeutic targets. As single-cell multi-omics technologies continue to evolve, integrated molecular profiling is expected to play a pivotal role in translating basic research into precision medicine for Parkinson's disease (Hasin et al., 2017; Smajić et al., 2022).

7. DISEASE PATHWAYS REVEALED BY SINGLE-CELL MULTI-OMICS

Single-cell multi-omics has transformed our understanding of Parkinson's disease (PD) by identifying molecular pathways that are disrupted within specific neuronal and glial cell populations. Unlike conventional molecular studies, which provide averaged signals from mixed tissues, single-cell approaches reveal cell-type-specific alterations that contribute to disease onset and progression. These technologies have demonstrated that mitochondrial dysfunction, protein aggregation, oxidative stress, impaired autophagy, neuroinflammation, and dysregulated cell death pathways act together to drive progressive neurodegeneration. Understanding these interconnected mechanisms is essential for identifying disease biomarkers and developing targeted therapeutic strategies (Agarwal et al., 2020; Smajić et al., 2022).

7.1 Mitochondrial Dysfunction

Mitochondria are the primary source of cellular energy and play a critical role in maintaining neuronal survival. In PD, mitochondrial dysfunction results in reduced ATP production, impaired oxidative phosphorylation, and excessive generation of reactive oxygen species (ROS). Single-cell transcriptomic studies have identified altered expression of mitochondrial genes specifically within vulnerable dopaminergic neurons, indicating that impaired energy metabolism is an early event in disease progression. Mutations in genes such as PINK1, PARK2, and DJ-1 further disrupt mitochondrial quality control, increasing neuronal susceptibility to degeneration (Agarwal et al., 2020; Pickrell & Youle, 2015).

7.2 Protein Misfolding

Protein homeostasis is essential for normal neuronal function. In Parkinson's disease, abnormal protein folding leads to accumulation of toxic protein aggregates that interfere with intracellular signaling and organelle function. Single-cell analyses have shown that genes regulating protein folding and molecular chaperones are significantly altered in dopaminergic neurons, suggesting impaired proteostasis contributes to selective neuronal vulnerability (Smajić et al., 2022).

7.3 Ubiquitin–Proteasome System

The ubiquitin–proteasome system (UPS) is responsible for removing damaged or misfolded proteins. Dysfunction of this pathway results in intracellular accumulation of toxic proteins and accelerates neuronal degeneration. Mutations affecting Parkin (PARK2) and other UPS-associated proteins impair protein degradation and promote α-synuclein accumulation. Single-cell studies have demonstrated reduced expression of ubiquitination-related genes in vulnerable neuronal populations, highlighting UPS dysfunction as a major contributor to PD pathology (Pickrell & Youle, 2015).

7.4 Autophagy–Lysosomal Pathway

Autophagy is a cellular recycling process that removes damaged organelles and aggregated proteins through lysosomal degradation. Impairment of this pathway results in defective clearance of α-synuclein and dysfunctional mitochondria. Single-cell transcriptomic analyses have identified dysregulation of autophagy-associated genes in dopaminergic neurons and glial cells, suggesting impaired autophagic flux contributes to progressive neurodegeneration. Genetic variants in GBA1, LRRK2, and ATP13A2 further support the importance of lysosomal dysfunction in PD (Menzies et al., 2017).

7.5 Oxidative Stress

Oxidative stress occurs when reactive oxygen species exceed the antioxidant capacity of the cell. Dopaminergic neurons are particularly vulnerable because dopamine metabolism itself generates free radicals. Excessive oxidative stress damages DNA, proteins, and membrane lipids, leading to mitochondrial dysfunction and neuronal apoptosis. Single-cell sequencing has identified increased oxidative stress-related gene expression in susceptible neuronal populations, indicating that oxidative injury is closely linked with disease progression (Dexter & Jenner, 2013).

7.6 Neuroinflammation

Chronic neuroinflammation is a prominent feature of Parkinson's disease. Activated microglia and reactive astrocytes release inflammatory cytokines, chemokines, nitric oxide, and reactive oxygen species that amplify neuronal injury. Single-cell studies have revealed distinct inflammatory glial subpopulations with either neurotoxic or neuroprotective functions, emphasizing the complexity of immune responses in PD. Persistent neuroinflammation contributes not only to neuronal degeneration but also to disease progression and symptom severity (Agarwal et al., 2020; Hickman et al., 2018).

7.7 Synaptic Dysfunction

Synaptic abnormalities often precede neuronal loss in Parkinson's disease. Altered dopamine release, impaired synaptic vesicle trafficking, and defective neurotransmitter recycling disrupt communication between neurons and impair motor control. Single-cell transcriptomics has demonstrated dysregulation of genes involved in synaptic organization, vesicle transport, and neurotransmitter signaling, suggesting that synaptic dysfunction is an early pathological event (Smajić et al., 2022).

7.8 Calcium Dysregulation

Intracellular calcium plays a vital role in neuronal excitability and neurotransmitter release. Dopaminergic neurons rely on continuous calcium influx for autonomous pacemaker activity, making them particularly susceptible to calcium overload. Excess intracellular calcium increases mitochondrial stress, promotes oxidative damage, and activates apoptotic pathways. Single-cell analyses indicate altered calcium signaling genes in vulnerable neuronal populations, supporting calcium dysregulation as an important mechanism of selective neurodegeneration (Surmeier et al., 2017).

7.9 Cell Death Pathways

Progressive neuronal loss in PD results from activation of multiple programmed cell death pathways. Besides apoptosis, recent studies have identified necroptosis, ferroptosis, and pyroptosis as important contributors to dopaminergic neuron degeneration. Single-cell technologies have enabled characterization of these pathways within specific neuronal and glial populations, providing new opportunities for targeted therapeutic intervention (Kamath et al., 2022).

7.10 Ferroptosis

Ferroptosis is an iron-dependent form of regulated cell death characterized by excessive lipid peroxidation and oxidative membrane damage. Increased iron accumulation within the substantia nigra is a well-recognized feature of Parkinson's disease. Single-cell studies suggest that dopaminergic neurons exhibit altered iron metabolism and antioxidant defense mechanisms, making them particularly vulnerable to ferroptotic cell death (Stockwell et al., 2020).

7.11 Pyroptosis

Pyroptosis is an inflammatory form of programmed cell death mediated by inflammasome activation and gasdermin pore formation. Activated microglia release inflammatory cytokines such as IL-1β and IL-18, amplifying neuroinflammation and promoting neuronal injury. Emerging evidence suggests that pyroptosis contributes to chronic inflammatory responses observed during PD progression (Cookson, 2019).

7.12 Necroptosis

Necroptosis is a programmed necrotic pathway regulated by receptor-interacting protein kinases (RIPK1, RIPK3) and mixed-lineage kinase domain-like protein (MLKL). Activation of necroptosis results in membrane rupture, inflammation, and neuronal death. Recent experimental studies indicate that inhibition of necroptotic signaling may reduce neurodegeneration and improve neuronal survival in Parkinson's disease models, highlighting this pathway as a promising therapeutic target (Venderova & Park, 2012).

8. BIOMARKER DISCOVERY THROUGH SINGLE-CELL TECHNOLOGIES

The identification of reliable biomarkers is essential for the early diagnosis, monitoring, and treatment of Parkinson's disease (PD). Traditional biomarkers often fail to detect early pathological changes because they reflect averaged molecular alterations from heterogeneous tissues. Single-cell technologies have overcome this limitation by enabling high-resolution analysis of individual cell populations, allowing researchers to identify cell-type-specific molecular signatures associated with disease onset and progression. Integration of transcriptomics, proteomics, metabolomics, and spatial multi-omics has accelerated the discovery of novel biomarkers that may improve diagnostic accuracy and facilitate precision medicine in PD (Smajić et al., 2022; Agarwal et al., 2020).

Unlike conventional approaches, single-cell analyses can identify subtle molecular changes within vulnerable dopaminergic neurons, reactive glial cells, and vascular cells before extensive neurodegeneration occurs. These biomarkers not only improve disease detection but also provide valuable information regarding disease stage, therapeutic response, and patient-specific molecular profiles.

8.1 Blood Biomarkers

Blood-based biomarkers are attractive because sample collection is minimally invasive, inexpensive, and suitable for repeated clinical monitoring. Recent studies have identified altered levels of inflammatory cytokines, neurofilament light chain (NfL), α-synuclein species, microRNAs, and circulating immune-cell signatures in patients with Parkinson's disease. Single-cell transcriptomic analysis of peripheral blood immune cells has further revealed disease-associated alterations in monocytes, T lymphocytes, and natural killer cells, suggesting that peripheral immune responses reflect ongoing neurodegeneration (Bloem et al., 2021; Smajić et al., 2022).

8.2 Cerebrospinal Fluid (CSF) Biomarkers

Cerebrospinal fluid directly reflects biochemical changes occurring within the central nervous system and therefore represents one of the most informative sources of PD biomarkers. Reduced dopamine metabolites, abnormal α-synuclein species, neurofilament light chain, tau protein, lysosomal enzymes, and inflammatory mediators have all been investigated as potential diagnostic indicators. Single-cell and multi-omics approaches have improved the identification of CSF biomarker panels capable of distinguishing PD from other neurodegenerative disorders with greater sensitivity and specificity (Poewe et al., 2017).

8.3 Extracellular Vesicles

Extracellular vesicles (EVs), including exosomes, are membrane-bound particles released by neurons and glial cells that transport proteins, lipids, RNA, and microRNAs between cells. Because EVs cross the blood–brain barrier, they provide a non-invasive source of brain-derived molecular information. In Parkinson's disease, extracellular vesicles contain disease-associated molecules such as α-synuclein, LRRK2 protein, inflammatory mediators, and regulatory RNAs, making them promising biomarkers for early diagnosis and disease monitoring (Thompson et al., 2022).

8.4 Cell-Free RNA

Cell-free RNA (cfRNA) consists of extracellular RNA fragments circulating in blood and other body fluids. Advances in next-generation sequencing have enabled sensitive detection of disease-associated messenger RNAs, microRNAs, and long non-coding RNAs. Altered expression of several circulating microRNAs involved in mitochondrial function, inflammation, and protein degradation has been associated with Parkinson's disease, suggesting that cfRNA may serve as a minimally invasive molecular biomarker for disease progression and therapeutic response (Smajić et al., 2022).

8.5 Imaging Biomarkers

Neuroimaging complements molecular biomarkers by providing structural and functional information about the brain. Positron emission tomography (PET), dopamine transporter single-photon emission computed tomography (DAT-SPECT), magnetic resonance imaging (MRI), and neuromelanin-sensitive MRI enable visualization of dopaminergic neuron loss, nigrostriatal degeneration, and neuroinflammatory changes. Combining imaging with single-cell molecular profiling enhances disease characterization and supports earlier diagnosis of Parkinson's disease (Bloem et al., 2021).

8.6 Multi-Omics Biomarker Panels

Individual biomarkers often lack sufficient sensitivity or specificity for clinical diagnosis. Therefore, recent research focuses on integrating genomic, transcriptomic, proteomic, metabolomic, lipidomic, and imaging data into comprehensive multi-omics biomarker panels. Artificial intelligence and machine learning algorithms further improve biomarker selection by identifying complex molecular patterns associated with disease onset and progression. Such integrated biomarker panels are expected to facilitate earlier diagnosis, patient stratification, prediction of disease progression, and personalized therapeutic decision-making in Parkinson's disease (Hasin et al., 2017; Smajić et al., 2022).

9. PRECISION THERAPEUTICS EMERGING FROM SINGLE-CELL RESEARCH

Recent advances in single-cell sequencing and multi-omics technologies have significantly influenced the development of precision therapeutics for Parkinson's disease (PD). Traditional treatments, including levodopa and dopamine agonists, primarily alleviate symptoms without preventing progressive neuronal degeneration. In contrast, single-cell analyses have identified cell-type-specific molecular alterations that enable the development of targeted therapies aimed at modifying disease progression. These technologies have facilitated the identification of vulnerable neuronal populations, disease-associated signaling pathways, and patient-specific therapeutic targets, thereby advancing the concept of personalized medicine in PD (Smajić et al., 2022; Bloem et al., 2021).

By integrating transcriptomic, epigenomic, proteomic, and metabolomic information at single-cell resolution, researchers can better understand disease heterogeneity and predict individual therapeutic responses. This precision medicine approach has accelerated the development of gene therapies, RNA-based therapeutics, stem cell transplantation, nanomedicine, genome editing, and artificial intelligence (AI)-guided drug discovery (Agarwal et al., 2020).

9.1 Gene Therapy

Gene therapy aims to correct or compensate for genetic defects associated with Parkinson's disease by delivering therapeutic genes directly into the brain. Viral vectors, particularly adeno-associated viruses (AAVs), are commonly used to deliver genes encoding neuroprotective factors, dopamine-synthesizing enzymes, or proteins involved in mitochondrial function. Therapeutic strategies targeting GBA1, LRRK2, SNCA, PINK1, and PARK2 are currently under investigation. Single-cell transcriptomic studies help identify patients who may benefit most from gene-based interventions by revealing cell-specific gene expression patterns and molecular abnormalities (Poewe et al., 2017; Smajić et al., 2022).

9.2 RNA Therapeutics

RNA-based therapies have emerged as promising approaches for selectively regulating disease-associated gene expression. Small interfering RNA (siRNA), antisense oligonucleotides (ASOs), and microRNA-based therapies can reduce the production of toxic proteins such as α-synuclein or modulate inflammatory pathways. Single-cell sequencing enables identification of cell-type-specific RNA targets, improving therapeutic specificity while minimizing off-target effects. Several RNA-targeted therapies are currently being evaluated for their ability to slow disease progression and preserve neuronal function (Bennett et al., 2021).

9.3 Stem Cell Therapy

Stem cell transplantation offers the potential to replace lost dopaminergic neurons and restore dopamine production within the nigrostriatal pathway. Human embryonic stem cells, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells have demonstrated encouraging results in preclinical and early clinical studies. Single-cell transcriptomics plays an essential role in characterizing transplanted cells, monitoring differentiation into authentic dopaminergic neurons, and evaluating graft survival and integration within host neural circuits. These analyses improve the safety and efficacy of regenerative therapies for Parkinson's disease (Barker et al., 2020).

9.4 CRISPR-Based Genome Editing

CRISPR-Cas genome editing has emerged as a powerful tool for correcting disease-causing mutations associated with familial Parkinson's disease. Genome editing strategies targeting genes such as SNCA, LRRK2, PINK1, and PARK2 have shown promising results in experimental models. Combined with single-cell sequencing, CRISPR technology enables precise evaluation of editing efficiency, gene expression changes, and potential off-target effects, thereby facilitating the development of personalized genetic therapies (Doudna, 2020).

9.5 Nanomedicine

Nanotechnology has improved targeted drug delivery by enhancing therapeutic penetration across the blood–brain barrier (BBB). Nanoparticles, liposomes, polymeric carriers, dendrimers, and lipid-based nanocarriers can deliver neuroprotective drugs, antioxidants, RNA molecules, and gene-editing components directly to affected neuronal populations. Single-cell analyses assist in evaluating nanoparticle distribution, cellular uptake, and therapeutic responses at the individual cell level, thereby optimizing nanomedicine-based treatment strategies (Saraiva et al., 2021).

9.6 Targeted Drug Delivery

Conventional pharmacological treatments often affect multiple tissues and produce systemic adverse effects. Targeted drug delivery systems aim to selectively deliver therapeutic agents to vulnerable neuronal populations while minimizing toxicity. Advances in ligand-mediated nanoparticles, antibody-conjugated drug carriers, and exosome-based delivery systems have improved therapeutic precision. Single-cell molecular profiling facilitates identification of cell-specific receptors and signaling pathways that can be exploited for targeted drug delivery (Agarwal et al., 2020).

9.7 AI-Guided Drug Discovery

Artificial intelligence (AI) and machine learning are transforming drug discovery by integrating large-scale genomic, transcriptomic, proteomic, imaging, and clinical datasets. AI algorithms can identify disease-associated molecular targets, predict drug–target interactions, prioritize candidate compounds, and accelerate drug repurposing. Combined with single-cell multi-omics, AI enables identification of patient-specific therapeutic strategies and supports precision medicine approaches for Parkinson's disease (Topol, 2019; Smajić et al., 2022).

9.8 Personalized Medicine

Personalized medicine aims to tailor therapeutic interventions according to each patient's genetic profile, molecular characteristics, disease stage, and predicted treatment response. Single-cell multi-omics provides detailed information about individual cellular composition and molecular alterations, allowing clinicians to classify patients into biologically distinct subgroups. This approach supports individualized treatment selection, prediction of therapeutic efficacy, and optimization of long-term disease management. As multi-omics datasets continue to expand, personalized medicine is expected to become a central component of future Parkinson's disease care (Hasin et al., 2017).

10. ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN SINGLE-CELL PARKINSON'S DISEASE RESEARCH

Artificial intelligence (AI) and machine learning (ML) have become indispensable tools for analyzing the enormous datasets generated by single-cell sequencing and multi-omics technologies. These computational approaches enable rapid processing of millions of cells, identification of disease-associated molecular patterns, prediction of cellular behavior, and integration of complex biological information. In Parkinson's disease (PD), AI-driven analyses have significantly improved the understanding of cellular heterogeneity, molecular mechanisms, biomarker discovery, and therapeutic target identification. By combining AI with single-cell multi-omics, researchers can better characterize disease progression and develop personalized therapeutic strategies, making precision medicine increasingly achievable (Smajić et al., 2022; Topol, 2019).

Machine learning algorithms can analyze transcriptomic, epigenomic, proteomic, metabolomic, and clinical datasets simultaneously, identifying subtle molecular signatures that are often undetectable using conventional statistical methods. These computational advances have accelerated biomarker discovery, patient stratification, drug development, and prediction of therapeutic outcomes in Parkinson's disease (Libbrecht & Noble, 2015).

10.1 Cell Annotation

One of the primary applications of AI in single-cell research is automated cell annotation. Machine learning algorithms classify individual cells according to their gene expression profiles, enabling rapid identification of dopaminergic neurons, astrocytes, microglia, oligodendrocytes, endothelial cells, and other brain cell populations. Automated annotation reduces manual bias and improves the accuracy of large-scale cellular atlases, facilitating comparison between healthy and Parkinsonian brain tissues (Agarwal et al., 2020).

10.2 Disease Prediction

Artificial intelligence can identify molecular signatures associated with early Parkinson's disease before the appearance of clinical symptoms. By integrating genetic, transcriptomic, imaging, and clinical information, predictive models estimate disease susceptibility, progression rate, and patient prognosis. These predictive systems may support earlier diagnosis and timely therapeutic intervention, ultimately improving patient outcomes (Topol, 2019).

10.3 Drug Repurposing

Developing new drugs for neurodegenerative diseases is time-consuming and expensive. AI-based drug repurposing accelerates this process by identifying approved drugs that may target disease-associated molecular pathways. Machine learning algorithms analyze large pharmacological databases together with single-cell transcriptomic data to predict compounds capable of restoring normal cellular function. This strategy shortens drug development timelines while reducing research costs and clinical risk (Pushpakom et al., 2019).

10.4 Multi-Omics Integration

Single-cell multi-omics generates diverse datasets that require sophisticated computational analysis. AI integrates genomic, transcriptomic, epigenomic, proteomic, metabolomic, and imaging information into unified molecular networks. This comprehensive approach enables researchers to identify regulatory pathways, discover biomarkers, understand cell–cell interactions, and reveal mechanisms underlying selective neuronal vulnerability in Parkinson's disease. Integrated analyses also improve patient stratification and facilitate personalized therapeutic decision-making (Hasin et al., 2017; Smajić et al., 2022).

10.5 Digital Twin Models

Digital twin technology is an emerging concept that combines AI with patient-specific biological data to generate a virtual representation of an individual patient. By integrating clinical information with single-cell multi-omics data, digital twins can simulate disease progression, predict therapeutic responses, and evaluate personalized treatment strategies before clinical implementation. Although still in its early stages, this technology has considerable potential to support individualized management of Parkinson's disease and optimize precision medicine approaches (Björnsson et al., 2020).

CONCLUSION

Parkinson's disease (PD) is a complex and progressive neurodegenerative disorder characterized by selective degeneration of dopaminergic neurons and widespread dysfunction of multiple neuronal and non-neuronal cell populations. Traditional molecular approaches have provided valuable insights into disease biology; however, they have been limited in their ability to resolve the extensive cellular heterogeneity of the human substantia nigra. The emergence of single-cell and single-nucleus sequencing technologies, together with multi-omics integration, has fundamentally transformed the understanding of PD by revealing cell-type-specific molecular signatures, regulatory networks, and intercellular interactions that drive disease initiation and progression (Agarwal et al., 2020; Smajić et al., 2022).

Single-cell analyses have demonstrated that Parkinson's disease extends beyond the degeneration of dopaminergic neurons and involves coordinated dysfunction of astrocytes, microglia, oligodendrocytes, oligodendrocyte precursor cells, endothelial cells, and other supporting cell populations. These studies have identified key pathogenic mechanisms, including mitochondrial dysfunction, oxidative stress, α-synuclein aggregation, impaired autophagy, neuroinflammation, synaptic dysfunction, calcium dysregulation, and abnormal protein degradation. The integration of transcriptomic, epigenomic, proteomic, metabolomic, and spatial omics data has further improved our understanding of these interconnected pathways and highlighted novel biomarkers and therapeutic targets that were previously unrecognized (Bloem et al., 2021; Kamath et al., 2022).

Importantly, advances in single-cell multi-omics, artificial intelligence, and machine learning are accelerating biomarker discovery, improving patient stratification, and enabling the development of precision therapeutic strategies. Emerging approaches, including gene therapy, RNA therapeutics, stem cell transplantation, CRISPR-based genome editing, nanomedicine, and AI-assisted drug discovery, have the potential to move beyond symptomatic management toward disease-modifying interventions. Although many of these strategies remain in the preclinical or early clinical stages, they represent promising avenues for personalized treatment based on the molecular characteristics of individual patients.

Despite these remarkable advances, several challenges remain before single-cell technologies can be routinely implemented in clinical practice. Technical variability, limited availability of high-quality human brain tissue, high analytical costs, batch effects, data standardization, and the integration of large multi-omics datasets continue to limit widespread clinical translation. Future research should focus on developing standardized analytical pipelines, expanding longitudinal patient cohorts, improving spatial and temporal resolution of single-cell analyses, and validating candidate biomarkers and therapeutic targets through multicenter clinical studies.

In summary, single-cell multi-omics has ushered in a new era of Parkinson's disease research by providing an unprecedented understanding of the cellular and molecular mechanisms underlying neurodegeneration. Continued integration of advanced sequencing technologies, computational biology, and precision medicine approaches is expected to facilitate earlier diagnosis, identify robust biomarkers, and accelerate the development of personalized disease-modifying therapies. These advances hold significant promise for improving clinical outcomes and enhancing the quality of life of individuals living with Parkinson's disease.

REFERENCES

1. Agarwal D, Sandor C, Volpato V, Caffrey TM, Monzón-Sandoval J, Bowden R, et al. A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders. Nat Commun. 2020;11:4183.
2. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284–2303.
3. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.
4. Smajić S, Prada-Medina CA, Landoulsi Z, Dietrich C, Jarazo J, Henck J, et al. Single-cell technologies in Parkinson's disease research. Nat Rev Neurol. 2022;18:423–436.
5. Kamath T, Abdulraouf A, Kostas JC, et al. Single-cell genomic profiling of the human brain in health and disease. Nature. 2022;604:509–520.
6. GBD 2021 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990–2021. Lancet Neurol. 2024;23:112–128.
7. Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132–144.
8. Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18:101–113.
9. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197–211.
10. Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015;85:257–273.
11. Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. J Neurochem. 2016;139(Suppl 1):216–231.
12. Menzies FM, Fleming A, Rubinsztein DC. Compromised autophagy and neurodegenerative diseases. Nat Rev Neurosci. 2017;18:345–361.
13. Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21:1359–1369.
14. Liddelow SA, Barres BA. Reactive astrocytes: production, function and therapeutic potential. Immunity. 2017;46:957–967.
15. Sweeney MD, Kisler K, Montagne A, Toga AW, Zlokovic BV. The role of brain vasculature in neurodegenerative disorders. Nat Neurosci. 2019;22:1573–1583.
16. Corces MR, Shcherbina A, Kundu S, et al. Single-cell epigenomic analyses implicate candidate causal variants in Alzheimer's and Parkinson's diseases. Nat Genet. 2020;52:1158–1168.
17. Stuart T, Satija R. Integrative single-cell analysis. Nat Rev Genet. 2019;20:257–272.
18. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18:83.
19. Kelly RT. Single-cell proteomics: progress and prospects. Mol Cell Proteomics. 2020;19:1739–1748.
20. Johnson ECB, et al. Multi-omics approaches in neurodegenerative diseases. Nat Rev Neurol. 2021;17:451–465.
21. Fanning S, Selkoe D, Dettmer U. Parkinson's disease: proteinopathy or lipidopathy? NPJ Parkinsons Dis. 2020;6:3.
22. Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol. 2020;19:170–178.
23. Marx V. Method of the Year: Spatially resolved transcriptomics. Nat Methods. 2021;18:9–14.
24. Regev A, Teichmann SA, Lander ES, et al. The Human Cell Atlas. eLife. 2017;6:e27041.
25. Yao Z, van Velthoven CTJ, Nguyen TN, et al. A transcriptomic and epigenomic cell atlas of the mouse primary motor cortex. Nature. 2021;598:103–110.
26. Bennett CF, Krainer AR, Cleveland DW. Antisense oligonucleotide therapies for neurodegenerative diseases. Nat Rev Drug Discov. 2021;20:783–802.
27. Barker RA, Drouin-Ouellet J, Parmar M. Cell-based therapies for Parkinson disease—past insights and future potential. Nat Rev Neurol. 2020;16:343–356.
28. Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578:229–236.
29. Saraiva C, Praça C, Ferreira R, et al. Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier. J Control Release. 2021;330:394–413.
30. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25:44–56.
31. Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. Nat Rev Genet. 2015;16:321–332.
32. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41–58.
33. Björnsson B, Borrebaeck C, Elander N, et al. Digital twins to personalize medicine. Genome Med. 2020;12:4.
34. Thompson AG, Gray E, Heman-Ackah SM, et al. Extracellular vesicles in neurodegenerative disease. Nat Rev Neurol. 2022;18:499–513.
35. Stockwell BR, Jiang X, Gu W. Emerging mechanisms and disease relevance of ferroptosis. Cell. 2020;181:448–464.
36. Cookson MR. The role of inflammation in Parkinson's disease. Nat Rev Neurosci. 2019;20:205–218.
37. Tang F, Barbacioru C, Wang Y, et al. Advances in single-cell sequencing technologies. Nat Rev Genet. 2019;20:631–656.
38. Yang W, Hamilton JL, Kopil C, et al. Current and projected future economic burden of Parkinson's disease in the United States. NPJ Parkinsons Dis. 2020;6:15.
39. Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson's disease: a special essay on the 200th anniversary of the Shaking Palsy. Mov Disord. 2017;32:1264–1310.
40. Brundin P, Dave KD, Kordower JH. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017;298:225–235.
41. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18:435–450.
42. Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Neuron. 2013;77:8–27.
43. Sulzer D, Surmeier DJ. Neuronal vulnerability and Parkinson's disease. Mov Disord. 2013;28:715–724.
44. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386:896–912.
45. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci for Parkinson's disease. Lancet Neurol. 2019;18:1091–1102.
46. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–376.
47. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12:723–738.
48. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 7th ed. New York: Garland Science; 2022.
49. Lodish H, Berk A, Kaiser CA, et al. Molecular Cell Biology. 9th ed. New York: W.H. Freeman; 2021.
50. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. 8th ed. New York: W.H. Freeman; 2021.